Category: ACN Newswire

NEW YORK, Apr 24, 2026 - (ACN Newswire via SeaPRwire.com) - FastX today announces the official launch of its platform, a next-generation exchange built for professional and active traders who require institutional‑grade tools without surrendering custody or control of their assets. FastX goes live globally on 5 May, with traders able to access the platform directly at fastx.co.FastX combines deep on‑chain liquidity, multi‑asset perpetual futures markets, and an advanced copy-trading engine designed to bridge the gap between traditional finance and the decentralized digital asset ecosystem. By leveraging blockchain technology, the platform delivers low‑latency mirroring of trades across major decentralized networks worldwide—while keeping users in full control of their own wallets and risk."FastX was created by traders for traders," said Adelene, Chief Executive Officer of FastX. "We've spent our careers on Wall Street desks and in crypto markets, and we've seen the same problems repeat: opaque execution, misaligned incentives, and copytrading systems that ask users to blindly outsource decisions. FastX is our answer—a decentralised, transparent infrastructure layer where traders keep custody, and technology works to augment, not replace, their edge."Backed by a team of veteran traders with more than 50 years of combined experience across top Wall Street institutions and leading crypto trading firms, FastX is built from the ground up as a decentralised protocol. Users connect their own wallets, maintain self‑custody at all times, and interact with smart contracts that execute trades on‑chain, rather than relying on a centralised broker or custodial exchange.At launch, FastX will offer:Deep, on‑chain liquidity across a wide range of perpetual markets, designed to support serious position sizes with tight spreads and minimal slippage.A fast, intuitive trading interface accessible directly via fastx.co, allowing traders to plug in with their preferred wallet and start trading in minutes.A transparent affiliate and points system that shares a meaningful portion of platform fees with the community and rewards traders and partners who help grow liquidity and volume.The flagship feature of FastX is its next‑generation copytrading system. Unlike traditional social trading products that mirror orders on a single venue with unpredictable delays, FastX's engine is designed to route and synchronise copy trades across major decentralised exchanges, layering those capabilities on top of FastX's own liquidity.The result is a copytrading experience that aims to:Minimise latency between lead and follower execution.Mitigate structural risks such as slippage, desync, and obvious forms of manipulation.Exploit decentralised advantages, such as transparent on‑chain track records and programmable risk controls, without turning the platform into a centralised black box."Copytrading has always been typecast as a blind, autonomous disaster waiting to happen," Adelene added. "FastX takes the opposite stance. We use technology to bring more transparency, not less—on‑chain track records, built‑in risk parameters, and infrastructure that reduces front‑running and execution games wherever possible. Over time, our goal is to layer AI‑driven intelligence on top of this foundation so that users can benefit from advanced analytics and risk management, rather than just 'follow and hope'."FastX is currently seed‑funded by a network of angels deeply embedded in the global crypto trading ecosystem. These backers share a common view that the next generation of markets will be built on open, verifiable rails and that traders deserve better, more transparent instrumentation for expressing and managing risk. FastX is assembling a strong advisory board of experienced traders, market makers, and technologists to guide the exchange through its next phase of growth.As a decentralised protocol, FastX does not take custody of user funds and does not operate as a traditional broker. All positions, liquidations, and fee flows are visible on‑chain, giving traders clear, verifiable insight into how the system behaves under all market conditions."Our vision is simple," said Adelene. "We want professional‑grade perpetuals and intelligent copytrading to live where they belong: on transparent, decentralised infrastructure, not in a black box. Launching FastX on 5 May is the first step. From here, we'll continue to ship faster execution, smarter tooling, and AI‑enhanced copytrading that helps traders survive and thrive in 24/7 markets."Traders can learn more and access the exchange at https://fastx.co.About FastXFastX focuses on building decentralised financial infrastructure and tools for professional traders and sophisticated market participants. The company backs products that prioritise self‑custody, transparency, and robust risk management in rapidly evolving digital asset markets.Media ContactBrand: FastX Perpetuals ExchangeContact: Ella HuangWebsite: https://fastx.co/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group’s research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group’s business growth.BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profileMG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Rα therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunitiesAllergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Rα, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.2. Zheng, Ming et al. “Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.” Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.145613. White, P et al. “Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x4. Rosenblut, A et al. “Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.” Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x5. Bernstein, Jonathan A et al. “Allergic Rhinitis: A Review.” JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - The 3rd Smart Lighting Expo and the 17th Hong Kong International Lighting Fair (Spring Edition), organised by the Hong Kong Trade Development Council (HKTDC), successfully concluded today at the Hong Kong Convention and Exhibition Centre. The four-day fairs brought together some 900 exhibitors and attracted some 13,000 buyers from 114 countries and regions for on-site visits and sourcing. Buyer numbers recorded growth, including those from Asian markets such as Malaysia and the Philippines; European markets including France, Germany, the Netherlands, Russia and Türkiye; and North and South American markets, including Brazil, Canada and the US, highlighting Hong Kong’s role as a key global hub for lighting products and technology exchange.Jenny Koo, Deputy Executive Director of the HKTDC, said: "This year’s two lighting fairs attracted industry-leading enterprises who showcased cutting-edge high-performance, smart lighting and sustainable products and solutions. The events also attracted quality buyers from global markets. This helps companies diversify supply chains, explore new markets, and underscores Hong Kong’s strength as an ‘International Exhibition Capital’ which boosts efficient business platforms. The fairs are the preferred platform for the industry to showcase innovation, connect with global buyer networks and accelerate business development.”Survey findings: Respondents were most optimistic about the India and Australia marketsTo keep abreast of the latest industry developments, the HKTDC conducted an on-site survey during the fairs, interviewing 450 exhibitors and buyers. The findings show that overall confidence among exhibitors and buyers in future business development has shown a general increase.Key market outlook and product trend findings:49.1% of respondents expect overall sales to increase in the next 12 to 24 months, while 47.6% expect sales to remain stable.Respondents consider India (73.4%), Australia (71%), ASEAN countries (70.4%), and Japan (68.1%) to be promising or very promising target sales markets for lighting products over the next two years in terms of growth.In terms of new market development, exhibitor respondents are actively exploring Middle East (31.8%), Europe (29.5%), ASEAN countries (23.9%), Latin America (17.6%) and North America (14.8%).In the smart lighting segment, respondents identified home automation and intelligent lighting control systems (48.2%), energy saving lighting control solutions (38.2%), and outdoor smart security lighting systems (31.1%) as having the greatest growth potential over the next two years.Compared with conventional lighting products, respondents indicated that consumers are willing to pay an average premium of 29% for lighting products equipped with smart functions.Scenario-based displays and new zones enhance sourcing effectiveness, with positive trade outcomesThe newly launched “Light Lab” features various scenario-based and immersive designs, integrating lighting products into landscape, sports, cultural and artistic application settings. Shanghai Sansi Electronic Engineering showcased plant clamp lights and compact downlights suitable for museum applications. Guoli Zhu, Deputy Chief Engineer of the company said: “The Light Lab has effectively enhanced the presentation of our products, enabling buyers to more intuitively and swiftly grasp product features and their real-world application scenarios. This has successfully attracted buyers from Argentina, Canada, Germany, India, Japan and the US to visit our booth for in-depth discussions. We expect this to result in orders worth over US$1 million.”The Smart Lighting Expo also debuted the “Smart Display and Stage Lighting & Sound Zone” which displayed a wide range of intelligent display solutions. Industry leader Absen participated in the fair for the first time. Benjamin Tang, Senior Sales Engineer, said: “The new zone has effectively enhanced product visibility, attracting buyers from Eastern Europe, Oceania, North America, South America, and South Asia to our booth. These inquiries came from new clients across key sectors such as cultural tourism and stage engineering. We have also successfully engaged in several promising collaboration discussions with potential clients from the Dominican Republic, Hong Kong and Thailand, further strengthening the company’s market expansion plan. We estimate the value of orders from the expo will amount to US$930,000. Riding on this momentum, we have decided to join the Hong Kong International Lighting Fair (Autumn Edition) this year.”The newly launched “Leisure Lighting Zone” has injected new momentum into the Spring Lighting Fair. Rebecca Seo, CFO of NIZ, a first-time exhibitor from Korea, said: “The fair has provided us with an excellent platform to connect with international buyers. We have successfully connected with buyers from Denmark, Germany, Japan, and the US, and a well-known Japanese homeware retailer has already placed an on-site order. Thanks to the strong traffic generated by the new zone, we expect the fair to bring up to US$70 million in orders for our company this year."Supported by Zhongshan as the Special Partner City, the fairs featured the Zhongshan Guzhen Pavilion and Zhongshan Henglan Pavilion under the Zhongshan Smart Home Zone, presenting the manufacturing strength and competitiveness of the region’s lighting industry while supporting enterprises in “going global”. Merry Liu, Manager of Bairan Lighting, an industrial enterprise above designated size in Henglan, Zhongshan, said: “The two lighting fairs provide Zhongshan enterprises with an efficient ‘go-global’ gateway, enabling us to connect directly with buyers from Europe, the Middle East, South America, and Southeast Asia. This helps drive our products and brand onto the international stage. We expect to achieve US$2 million in sales.”During the fair, the HKTDC organised a buying mission to Zhongshan for the first time, visiting several lighting factories and participating in business matching meetings. This initiative aimed to deepen exchange and cooperation within the Zhongshan lighting supply chain. The visit successfully facilitated several substantive business collaborations; New Zealand buyer Spark100 Ltd established a connection with a Zhongshan lighting supplier, with a potential order value estimated between US$100,000 and US$300,000.This year’s exhibition also attracted buyers from the Middle East. Patrick Zhang, VP of sales of Tecnon Lighting Technology from the Shenzhen Pavilion, stated: “At this year’s fair, a buyer from the United Arab Emirates and a US buyer from a leading women’s fashion brand are likely to become our cooperation partners. We expect to generate US$2 million in sales turnover for our company.”As construction projects in the ASEAN region accelerate, market demand for smart lighting solutions continues to expand. Sambath HK, Manager of RS Decoration from Cambodia, stated, “I travelled here specifically to source lighting products for 14 new commercial building and luxury residential projects. I have already met with over 20 new suppliers and identified two potential partners offering smart street lights, solar lights, and decorative lighting products. I will initially purchase US$100,000 worth of smart street lights.”Driven by the Belt and Road Initiative, urban development in participating countries and regions are in full swing, fuelling a continuous surge in demand for high-efficiency and smart lighting products. Aigerim Beisekina, Supply Manager of Karelz.kz from Kazakhstan, said: “This is our first time visiting the twin lighting fairs, to find reliable suppliers for a solar-powered stadium and sports lighting for three international schools currently under construction in Kazakhstan. Through the Click2Match business matching platform, we have identified three potential suppliers from the Chinese Mainland and plan to purchase lighting equipment valued between US$600,000 and US$900,000.”During the fairs, multiple professional events were held, including the Asian Lighting Conference and the Smart Lighting Solutions Forum. Designers and industry representatives from different regions shared market trends, application cases and technological developments, providing forward-looking market insight for the industry.EXHIBITION+ model sustains post-fair business opportunitiesUnder the hybrid EXHIBITION+ model, the twin lighting fairs combined in-person sourcing with online meetings via the HKTDC’s Click2Match smart business-matching platform and hktdc.com sourcing platform. Click2Match will be available until 30 April to facilitate discussions between exhibitors and buyers around the world.Photo download: https://bit.ly/42m6sqDThe 3rd Smart Lighting Expo and the 17th Hong Kong International Lighting Fair (Spring Edition), organised by the Hong Kong Trade Development Council (HKTDC), successfully concluded today at the Hong Kong Convention and Exhibition Centre, attracted some 13,000 buyers from 114 countries and regions for on-site visits and sourcing.The newly launched “Light Lab” adopted a series of scenario-based and immersive designs, integrating lighting products directly into landscape, sports, cultural and artistic application settings, enabling buyers to better understand product features and practical applications.At the Spring Lighting Fair, the featured “Hall of Aurora” brought together 120 international and premium lighting brands, attracting numerous global buyers.The Shanghai Pudong Intelligent Lighting Association also returned to the Smart Lighting Expo for the third consecutive year, presenting the “Intelligent Ecosystem & IoT Supply Chain Zone”.As for the Spring Lighting Fair, exhibitors include the Xiamen Pavilion, and newly participating Changzhou Zouqu District Pavilion and Zhejiang Pavilion, further broadening industry exchange.The two fairs gathered numerous renowned brands and industry leaders, including Absen (photo), an LED display provider featured at the NBA All-Stars Games, the FIFA Qatar World Cup and Qatar Doha World Expo, and a Guinness World Record holder; and Shanghai Sansi, which supplies over 60% of the display screens in Times Square, New York.During the fairs, the HKTDC arranged various matching activities to connect buyers and exhibitors. The photo shows buyer Powermep from the UAE in discussion with an exhibitor.During the fairs, the HKTDC organised a buying mission to Zhongshan for the first time, visiting several lighting factories and participating in business matching meetings, strengthening exchange and cooperation within the Zhongshan lighting supply chain.The Smart Lighting Solution Forum was held on 21 April. Industry experts shared developments in smart home lighting systems and human-centric lighting for home entertainment as well as discussion of the eco-system of health and connected lighting supply chains.As part of the city’s mega-event economy, the Hong Kong Tourism Board (official exhibition promotion partner) arranged special “Cheung Po Tsai” Victoria Harbour night cruises during the fairs to enhance the business travel experience of convention and exhibition visitors.WebsitesHong Kong International Lighting Fair (Spring Edition): hklightingfairse.hktdc.com/tcSmart Lighting Expo: smartlightingexpo.hktdc.com/tcHKTDC Mediaroom: http://mediaroom.hktdc.com/enMedia enquiriesHKTDC’s Communications & Public Affairs Department:Stanley So Tel: (852) 2584 4049 Email: stanley.hp.so@hktdc.orgNavin Law Tel: (852) 2584 4525 Email: navin.cm.law@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SPRINGVILLE, UT, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Sisel International�today announced that it has appointed Pamela Ferry as General Manager of Australia and New Zealand as the company accelerates its expansion and transitions to full market operations across the region.Ferry brings more than 20 years of experience in the global direct selling industry, with a focus on international market expansion, distributor growth, and leadership development, including experience supporting the relaunch of underperforming markets and driving renewed growth. Throughout her career, she has held leadership roles focused on building strong teams, developing field leaders, and fostering long-term organizational success. An experienced presenter, trainer, and events professional, Ferry is recognized for her ability to connect with audiences and translate strategy into practical field execution. Her strengths in relationship building and education position her to play a key role in developing Sisel's distributor network and establishing a strong foundation in the region.The appointment comes at a pivotal stage as Sisel expands into the Australian market, with a focus on building infrastructure, enabling�distributor growth, and introducing its science-driven wellness solutions to new audiences. Ferry will lead efforts to develop market operations, strengthen field support, and drive sustainable growth across Australia and New Zealand."Australia represents an important opportunity for Sisel as we continue our international expansion," said Tom Mower Jr., CEO and Co-Founder of Sisel International. "Pamela brings not only deep industry experience, but a proven ability to develop leaders and build strong distributor networks. Her leadership will be instrumental as we establish a long-term presence in the region."About Sisel International Sisel International is a global health and wellness company dedicated to developing high-quality, science-driven products designed to support healthier living. Co-founded by Tom Mower Sr. and led by CEO Tom Mower Jr., Sisel creates supplements, personal care, home care, and wellness solutions formulated without harmful or unnecessary ingredients. Guided by its founding principles, the company is committed to innovation, safety, and quality while empowering individuals to pursue health, longevity, and personal success worldwide.Media Contact:Sisel InternationalMarketing TeamEmail:�marketing@sisel.netWebsite: www.sisel.netSOURCE: Sisel International Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - FastX today announces the official launch of its platform, a next-generation exchange built for professional and active traders who require institutional‑grade tools without surrendering custody or control of their assets. FastX goes live globally on 5 May, with traders able to access the platform directly at fastx.co.FastX combines deep on‑chain liquidity, multi‑asset perpetual futures markets, and an advanced copy-trading engine designed to bridge the gap between traditional finance and the decentralized digital asset ecosystem. By leveraging blockchain technology, the platform delivers low‑latency mirroring of trades across major decentralized networks worldwide—while keeping users in full control of their own wallets and risk."FastX was created by traders for traders," said Adelene, Chief Executive Officer of FastX. "We've spent our careers on Wall Street desks and in crypto markets, and we've seen the same problems repeat: opaque execution, misaligned incentives, and copytrading systems that ask users to blindly outsource decisions. FastX is our answer—a decentralised, transparent infrastructure layer where traders keep custody, and technology works to augment, not replace, their edge."Backed by a team of veteran traders with more than 50 years of combined experience across top Wall Street institutions and leading crypto trading firms, FastX is built from the ground up as a decentralised protocol. Users connect their own wallets, maintain self‑custody at all times, and interact with smart contracts that execute trades on‑chain, rather than relying on a centralised broker or custodial exchange.At launch, FastX will offer:Deep, on‑chain liquidity across a wide range of perpetual markets, designed to support serious position sizes with tight spreads and minimal slippage.A fast, intuitive trading interface accessible directly via fastx.co, allowing traders to plug in with their preferred wallet and start trading in minutes.A transparent affiliate and points system that shares a meaningful portion of platform fees with the community and rewards traders and partners who help grow liquidity and volume.The flagship feature of FastX is its next‑generation copytrading system. Unlike traditional social trading products that mirror orders on a single venue with unpredictable delays, FastX's engine is designed to route and synchronise copy trades across major decentralised exchanges, layering those capabilities on top of FastX's own liquidity.The result is a copytrading experience that aims to:Minimise latency between lead and follower execution.Mitigate structural risks such as slippage, desync, and obvious forms of manipulation.Exploit decentralised advantages, such as transparent on‑chain track records and programmable risk controls, without turning the platform into a centralised black box."Copytrading has always been typecast as a blind, autonomous disaster waiting to happen," Adelene added. "FastX takes the opposite stance. We use technology to bring more transparency, not less—on‑chain track records, built‑in risk parameters, and infrastructure that reduces front‑running and execution games wherever possible. Over time, our goal is to layer AI‑driven intelligence on top of this foundation so that users can benefit from advanced analytics and risk management, rather than just 'follow and hope'."FastX is currently seed‑funded by a network of angels deeply embedded in the global crypto trading ecosystem. These backers share a common view that the next generation of markets will be built on open, verifiable rails and that traders deserve better, more transparent instrumentation for expressing and managing risk. FastX is assembling a strong advisory board of experienced traders, market makers, and technologists to guide the exchange through its next phase of growth.As a decentralised protocol, FastX does not take custody of user funds and does not operate as a traditional broker. All positions, liquidations, and fee flows are visible on‑chain, giving traders clear, verifiable insight into how the system behaves under all market conditions."Our vision is simple," said Adelene. "We want professional‑grade perpetuals and intelligent copytrading to live where they belong: on transparent, decentralised infrastructure, not in a black box. Launching FastX on 5 May is the first step. From here, we'll continue to ship faster execution, smarter tooling, and AI‑enhanced copytrading that helps traders survive and thrive in 24/7 markets."Traders can learn more and access the exchange at https://fastx.co.About FastXFastX focuses on building decentralised financial infrastructure and tools for professional traders and sophisticated market participants. The company backs products that prioritise self‑custody, transparency, and robust risk management in rapidly evolving digital asset markets.Media ContactBrand: FastX Perpetuals ExchangeContact: Ella HuangWebsite: https://fastx.co/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Zurich, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Akkodis, a global leader in digital engineering consulting and part of the Adecco Group has been named a "Leader" by Information Services Group (ISG) in the ISG Provider Lens™ Digital Engineering Services 2026 reports, recognizing the company's strength across critical engineering and technology domains in Europe and the United States.Image: Akkodis named leader in ISG Digital Engineering Services 2026. Source: AkkodisAkkodis earned Leader status in the following quadrants:Augmented Design and R&D Services (Europe)Intelligent Operations and Connected Experiences (Europe)Integrated Platform and Application Services (Europe and U.S.)Leadership in augmented design & R&D servicesISG highlights Akkodis' expertise in end‑to‑end product development, including systems architecture, Model-based Systems Engineering (MBSE) integration, unified tool chains and multi‑domain engineering. The company's digital twin methodologies support deep physical-digital integration for safety‑critical products. By integrating engineering and digital toolchains, Akkodis accelerates agile product development from concept to lifecycle management across automotive, aerospace, rail and industrial sectors.ISG also recognizes Akkodis' leadership in software-defined vehicle (SDV) engineering, with capabilities spanning hardware-in-the-loop (HIL) automation, telemetry pipelines, cloud‑scale validation and AI‑supported analytics. This has been successfully showcased through the Akkodis SDV Academy where clients accelerate advanced driver‑assistance systems (ADAS) and SDV verification while addressing engineering talent gaps. Expertise in embedded systems, sensor fusion and real‑time software reinforces Akkodis' position across mobility, industrial and defense applications.Advancing intelligent operations & connected experiencesISG recognizes Akkodis for advancing industrial intelligence and transforming factory and mission-critical operations. Through smart commissioning frameworks, digital twins and advanced simulation tools, the company helps clients accelerate digital factory planning, reduce layout risks and improve overall equipment effectiveness (OEE). Akkodis also supports predictive quality and maintenance through acoustic sensing, physics-based AI and data-driven diagnostics. Its operations capabilities (including ruggedized hardware engineering, over-the-air (OTA) lifecycle management and industrial asset health solutions), have been applied across industries and asset-intensive environments requiring reliability, safety compliance, environmental resilience and long-term continuity.Strength in Integrated Platform & Application ServicesAkkodis' digital solutions advance AI‑led autonomous engineering by accelerating validation, enhancing quality and enabling compliance‑by‑design at scale. In Europe, ISG highlights Akkodis' Unified AI Platform, powered by AI-Core, alongside its deep expertise in cloud, hybrid and sovereign architectures, including AWS, Azure and sovereign deployments, which helps organizations balance agility with security, compliance and data residency requirements.In the U.S., ISG cites Akkodis' leadership in cloud‑native, MACH‑aligned modernization. Its AI‑enabled development frameworks embed intelligence into workflows, accelerating modernization and enabling personalized digital experiences. DevSecOps, compliance‑by‑design models and a secure, modular AI‑Core platform, enable Akkodis to provide scalable, cloud‑native innovation and flexible integration across modern enterprise and platform ecosystems."We are proud to receive this recognition from ISG which underscores the depth of Akkodis' global digital engineering expertise and our ability to combine AI‑driven engineering, cloud‑agnostic platforms and compliance‑by‑design at global scale to help clients innovate with Akkodis Intelligence across dynamic and complex environments," said Jo Debecker, President & CEO of Akkodis.Shirish Madhukar Kulkarni, Lead Analyst, ISG, said, "Akkodis uniquely combines deep engineering expertise with AI‑led digital twins and scalable platforms to enable faster product innovation, resilient operations, and connected, data‑driven experiences." Srinivasan P N, Senior Lead Analyst, ISG added, "Akkodis' leadership is rooted in four decades of European engineering excellence, where systems engineering, validation depth and software defined innovation converge through Akkodis Intelligence to deliver trusted, AI enabled digital engineering at scale."Media contactsAnne FriedrichSVP, Global Head of Communications, AkkodisM. +4915174633470E. anne.friedrich@adeccogroup.comLisa BushkaVP, External Communications, AkkodisM. +18604630770E. lisa.bushka@adeccogroup.comAbout AkkodisAkkodis is a global digital engineering consulting company that enables organizations to innovate and accelerate by applying technology to redefine how processes and products are developed, powered and optimized. With deep expertise across AI, data, cloud, edge and software engineering, we offer best-in-class technology consultancy. Through our strong, scalable delivery models and specialized talent, we provide end-to-end solutions, from strategy and consulting through implementation. Our commitment to Akkodis Intelligence helps businesses connect the exponential power of technology with the irreplaceable strengths of human thinking and collaboration. Part of the Adecco Group and headquartered in Switzerland, Akkodis brings together 40,000 engineers and digital experts in over 30 countries, with services that span Consulting, Solutions and Academy. With deep experience across the world's major industries, Akkodis empowers businesses to solve complex challenges and achieve sustainable impact. akkodis.com | LinkedIn | Instagram | Facebook | XAbout the Adecco GroupThe Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units - Adecco, Akkodis and LHH - across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). www.adeccogroup.comAbout ISGISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries-a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com.SOURCE: Akkodis Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月23日 - (亚太商讯 via SeaPRwire.com) - 全球ADC药物市场正经历爆发式增长，2024年市场规模突破250亿美元，其中前五大商业化产品的年度销售额均突破10亿美元，Padcev更是以近26亿美元的成绩证明了靶向Nectin-4 ADC的广阔前景。与此同时，中国创新药企不再满足于本土市场，纷纷将目光投向海外。在这一轮出海浪潮中，迈威生物凭借差异化的管线设计、积极的对外授权策略以及新兴市场的商业化落地，逐步展现出清晰的全球化路径。迈威生物成立于2017年，是一家具备从药物发现到商业化销售全产业链能力的中国创新制药公司。公司已于2022年1月在上海证券交易所科创板上市（股票代码：688062），此次赴港上市旨在构建「A+H」双融资平台，进一步打开国际资本通道，为海外商业化创造更便利的条件。核心产品获FDA多项认定，国内外临床试验启动截至目前，迈威生物拥有4款已上市产品及10款候选药物，覆盖肿瘤、免疫、骨科、眼科等领域。其中，核心产品9MW2821（靶向Nectin-4 ADC）在多个适应症上展现出全球领先的临床开发进度。在尿路上皮癌领域，该产品是在中国开发的同类靶点ADC中进展最快的，全球范围内仅次于已上市的Padcev；其联合特瑞普利单抗的一线疗法III期试验正在推进中，有望于2027年提交新药上市申请（NDA）。在宫颈癌领域，9MW2821更是全球首款进入关键III期试验阶段的靶向Nectin-4 ADC，该III期临床试验已于2024年9月启动，预计2027年完成。针对三阴性乳腺癌，9MW2821精准聚焦拓扑异构酶抑制剂ADC经治后的耐药患者这一差异化赛道，已在中国开展II期试验，并于2025年8月在美国启动I期研究，计划后续开展全球多中心II期或III期临床试验。目前，9MW2821已累计获得美国FDA授予的多项快速通道认定及孤儿药资格认定，并获中国国家药监局授予两项突破性疗法认定，充分验证了其全球同类最佳的潜力。除核心产品9MW2821外，迈威生物的ADC管线储备同样颇具看点。靶向B7-H3的7MW3711已在国内获批联合特瑞普利单抗及JS207等疗法的Ib/II期研究，并获FDA授予小细胞肺癌孤儿药资格，初步临床数据在肺癌、食管癌等实体瘤中显示出良好安全性与抗肿瘤活性。另一款靶向CDH17的7MW4911则在中美双轨并行，国内I期与美国I/II期临床同步推进，精准聚焦高发消化道肿瘤。两款产品的快速推进不仅丰富了公司ADC产品矩阵，更凸显了其在差异化靶点布局与全球临床开发上的创新执行力。超20亿美元对外授权，验证管线全球价值通过对外授权将早期管线的价值变现，同时加速已上市产品的商业化放量，迈威生物已形成清晰的商业闭环。2025年，公司总收入达到6.59亿元人民币，同比增长230.0%。其中对外授权收入4.09亿元，收入占比62%。主要授权合作包括：授予齐鲁制药在大中华区独家开发及商业化迈粒生(R)（长效G-CSF）的权利，获得首付款及里程碑付款；授予Disc在除大中华区及东南亚以外的全球范围内独家许可9MW3011（抗TMPRSS6单抗）的权利，潜在里程碑金额最高达4.125亿美元，并已达成II期试验里程碑；授予Calico在除大中华区以外的全球独家开发及商业化9MW3811（靶向IL-11单抗）的权利，潜在里程碑金额最高近6亿美元；授予Kalexo Bio在全球范围独家开发、生产和商业化双靶点siRNA候选药物的权利，潜在里程碑金额最高可达10亿美元，此外公司还有权获得其双位数A轮优先股股权。上述合作总潜在里程碑金额超过20亿美元，不仅为公司带来了即期现金流入，也证明了其创新管线的国际竞争力。通过精准选择深耕细分领域的合作伙伴并实施对外授权，公司已将创新管线的价值推向全球舞台；与此同时，依托自主研发夯实长期创新根基，迈威生物在早期价值变现与持续研发投入之间建立起良性循环，实现了全球化布局与内生增长的双重驱动，构建起可持续的创新发展范式。生物类似药持续落地，商业化网络持续扩张在产品出海方面，迈威生物以生物类似药作为切入新兴市场的突破口。2025年8月，迈利舒(R)及迈卫健(R)在巴基斯坦获批上市，成为巴基斯坦首个获批的Prolia(R)及Xgeva(R)生物类似药。此外，公司已与巴西、秘鲁、沙特阿拉伯、菲律宾等多个国家的领先制药公司签订合作协议，推动产品在当地的注册与商业化。2025年12月，君迈康(R)（阿达木单抗生物类似药）也在印度尼西亚获批上市，并已与16个国家订立海外合作协议。同时，公司自主研发的长效G-CSF迈粒生(R)于2025年5月获批上市，是首个全球上市的采用白蛋白长效融合技术开发的G-CSF药物，公司已将其在大中华区的独家开发及商业化权利授予齐鲁制药。依托齐鲁制药在肿瘤领域成熟的销售网络和强大的商业化能力，迈粒生(R)有望快速切入庞大的G-CSF市场，有效解决该领域大量未得到满足的医疗需求，在竞争激烈的市场中占据一席之地。这些海外上市进展表明，迈威生物不仅具备研发能力，更拥有将产品推向国际市场的注册与商业化执行力。对于新兴市场而言，高质量且具成本优势的生物类似药存在巨大未满足需求，迈威生物的提前布局有望在未来数年持续贡献收入增量。为支撑海外商业化布局，迈威生物始终坚持以国际标准构建质量体系。公司位于江苏泰州的生产基地严格符合中国GMP标准及欧盟EMA GMP标准，而正在建设的上海金山大规模商业化生产基地同样遵循欧盟EMA GMP标准设计。此外，公司的地舒单抗生产线已零缺陷通过哥伦比亚INVIMA的现场审计。基于此，迈卫健(R)（地舒单抗，120mg）和迈利舒(R)（地舒单抗，60mg）已成功实现海外商业化发货。接轨国际的质量管理体系不仅为产品在新兴市场的注册与商业化奠定了坚实基础，也确保了公司在全球供应链中的合规性与竞争力。结语迈威生物已构建起涵盖差异化ADC管线、对外授权落地、生物类似药海外上市及国际质量体系认证的全球化布局，实现了自主研发、对外授权与海外商业化的协同驱动。此次赴港上市不仅是其资本战略的关键一步，更将为其打开国际资本通道，加速海外临床研究、全球注册申报以及商业化网络拓展。在港股生物医药板块估值处于历史低位的当下，公司用扎实的管线与商业化成果，向国际投资者展示了中国创新药的务实路径。具备真正全球化能力的ADC新贵，值得长期关注。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Sinch Mailgun, part of Sinch, has released its Email Impact Report 2026, introducing new industry benchmarks across 10 high-volume sending sectors and revealing a gap between email performance and execution.Based on insights from more than 400 billion emails sent in 2025 and a global survey of over 1,200 email senders, the report shows that while email remains a critical, high-performing channel, poor deliverability is leaving significant revenue on the table. Nearly 18% of emails fail to reach the inbox, putting up to a fifth of potential return on investment at risk for many organisations.78% of respondents say email is critical to business success. At the same time, the research highlights a growing disconnect between performance and execution, driven by gaps in measurement, deliverability practices and AI application.“APAC businesses rely heavily on email to drive sales, loyalty and customer experience but many are not set up to capture its full value,” said Ginger Kidd, Vice President Marketing & Communications APAC at Sinch. “What we see in this data reflects what’s happening locally: brands are investing in email and seeing strong returns, yet there is still a high number of messages that never reach inboxes. For instance, in a market as competitive and cost-conscious as Australia, marketers simply can’t afford for emails to get lost in inboxes. When budgets are under pressure, fixing deliverability is one of the fastest ways to unlock more value from the spend they already have.”AI adoption is widespread, but its impact remains uneven. Many teams focus on basic use cases such as content generation, while higher-impact applications such as optimisation, segmentation and deliverability remain underutilised. Organisations that use AI more effectively are significantly more likely to report improved email performance.Ginger Kidd said: "Across the diverse markets of APAC, we’re seeing a common theme: marketers are enthusiastically adopting AI, but the initial focus has primarily been on content creation. The true opportunity now lies in leveraging AI for smarter decision-making. For instance, who to send to, how often, and with what level of risk. This strategic shift is the key to ensuring every campaign improves performance, not just adds volume.“The most sophisticated teams are already using AI to predict which subscribers are at risk of disengaging, to fine-tune send times and to protect sender reputation. That’s where we’re seeing a real uplift in performance, not just faster content production.”Key findings of the report include:60% of companies measuring email ROI report returns above $10 for every $1 spentMore than 1 in 10 achieve returns as high as 40:146% say AI improves speed and efficiency41% of teams use AI to generate email content23% say AI has not improved their email programs49% report improved email performance year-over-year79% plan to maintain or increase investment in emailFewer than half of organisations can confidently measure email ROIAbout the reportThe Email Impact Report 2026 combines:Data from 400+ billion emails sent in 2025Insights from 1,200+ email senders globallyBenchmarks across 10 high-volume industriesRead more about the report here.About SinchSinch’s vision is to connect every business with every customer, everywhere in the world. With the industry’s most trusted foundation for intelligent customer communications, Sinch powers over 900 billion customer interactions annually for more than 200,000 customers across the globe. Leading global companies, including AI innovators, rely on Sinch to strengthen customer relationships and deliver seamless experiences across messaging, email and voice. Profitable since its founding in 2008, Sinch generated net sales of USD 3 billion (SEK 27 billion) in 2025 and has over 4,000 Sinchers in 60 countries, with headquarters in Stockholm. Sinch is listed on Nasdaq Stockholm (XSTO: SINCH). Visit us at sinch.com.About Sinch MailgunSinch Mailgun is the email infrastructure platform built for developers and businesses that demand reliable, high-performance delivery at scale. Trusted by companies worldwide, Mailgun powers transactional, marketing, and programmatic email through a developer-first API, advanced deliverability tools, and real-time analytics. As part of Sinch — the industry’s most trusted foundation for intelligent customer communications — Mailgun connects businesses to their customers through every send, at every scale. Visit us at mailgun.com.For more information, please contact:Tracey ChooCommunications Manager, APAC at SinchE-mail: tracey.choo@sinch.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

宾夕法尼亚州费城, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - Datavault AI Inc.（“Datavault AI”或“公司”） （纳斯达克代码：DVLT），作为人工智能驱动的数据变现、资质认证、数字互动及现实世界资产（“RWA”）通证化技术的领导者，今日宣布获得美国专利第12,596,819号，并收到两项美国专利申请的准予通知。这一里程碑直接延续了公司于2025年12月获得的两项基础专利——区块链驱动的内容授权及代币化变现专利，进一步扩展了其强大的知识产权组合，其中以行业标杆性的碳信用代币化专利为代表。投资者关注要点一项新颁发的专利和两份准予通知书将保护范围扩展至三个高价值平台：AI验证的数据估值与变现、代币化虚拟位置融资，以及数字资产和DeFi的自动化纳税申报准备——直接解决了1099-DA合规挑战。通过抗量子加密和区块链不可篡改性，强化了公司的Sumerian®加密锚、DataValue®、DataScore®及信息数据交换®（IDE®）技术，为日益增长的代币化合约和授权协议提供了坚实支撑。该产品问世之际，正值首个完整的 IRS 1099-DA 申报季结束，此前据报道存在运营障碍——包括 Coinbase、Kraken 和 Gemini 的数据提交延迟——这充分证明了市场对 Datavault AI 自动化、代币化税务解决方案的明确需求。支持的应用场景包括代币化大宗商品（铜、黄金、贵金属）、农业/基因组/医疗数据资产、NIL数字孪生、资金支持的虚拟生物技术市场，以及智能税务自动化——这些功能可与公司的边缘GPU集群和HPC基础设施原生集成。该技术直接支撑Datavault AI实现2026年至少2亿美元营收的目标，加速其在金融科技、医疗保健、生物技术、能源、农业、体育娱乐及Web3领域的商业化进程，并开辟新的授权与合作机遇。最新专利保护范围美国专利号 12,596,819 - “数据估值与安全商业变现平台的方法及系统”（已授权）：涵盖端到端的许可型平台，涵盖自愿数据贡献、AI驱动的自动化估值、在Datavault®中的区块链代币化存储，以及在开放交易所上的交易（支持销售、许可、奖励、慈善捐赠等多种灵活的补偿途径）。美国专利申请号 17/842,220 - “虚拟位置融资系统及方法”（准予通知）：保护针对特定组织的虚拟位置的融资、认证及代币化运营，包括多币种捐赠、集成式活动与资产代币化、与投资组合匹配的广告，以及面向数据贡献者的补偿机制。美国专利申请号 17/507,459 - “报税准备平台及方法”（准予通知）：涵盖为客户和员工提供的自动化报税准备服务，包含针对数字资产和DeFi活动的专用代币化报税处理、后端表单处理，以及对不断变化的税法进行的动态调整——精准解决困扰首个1099-DA申报季的对账负担和可见性缺口。市场背景与利好因素这些专利申请使 Datavault AI 处于三个快速扩张市场的交汇点。代币化的现实世界资产（RWA）的链上价值已超过 300 亿美元（RWA.xyz 2025 年数据），波士顿咨询集团（BCG）和 ADDX 预测，到 2030 年全球市场规模将超过 16 万亿美元。全球数据货币化市场预计将从2024年的75.3亿美元增长至2033年的188亿美元（年复合增长率10.7%，SkyQuest Technology）。这项新的税务申报专利恰逢美国纳税人正经历美国国税局（IRS）1099-DA表数字资产经纪商申报制度实施后的首个完整纳税年度——其中总收入申报自2025年1月1日开始，特定交易的成本基础申报将于2026年1月1日生效——而行业内关于经纪商申报延迟以及跨钱包/跨链/跨DeFi对账的摩擦问题已广受关注。对投资者的影响与战略展望总体而言，已获授权的专利和获准的专利申请扩展了知识产权的覆盖范围，涵盖了将原始数据转化为代币化、可交易资产的创新技术，并实现了虚拟环境及数字资产组合的透明融资、变现和自动化税务处理。预计这些技术将与 Datavault AI 计划部署的边缘 GPU 集群和高性能计算基础设施无缝集成，从而加速 AI 估值处理和代币化合约的执行。“获得这项已授权专利并收到另外两项申请的准予通知，印证了我们在将无形数据转化为可验证、可变现资本方面的领导地位，以及在帮助组织以完全透明且用户可获补偿的方式为虚拟世界提供资金并运营方面的优势，”Datavault AI创始人兼首席执行官纳撒尼尔·T·布拉德利（Nathaniel T. Bradley）表示。“这些专利申请深化了我们的竞争护城河，并加速了我们在数据资产、实物资产及数字资产税务准备市场中抢占重要份额的进程——这将直接推动我们实现2026年2亿美元的营收目标，并扩大代币化合约的储备。”如需进一步了解 Datavault AI 的增长战略、商业化路线图，以及通过代币化和授权释放数据与知识产权价值的长期愿景，建议投资者观看 Tech Edge 近期对首席执行官纳撒尼尔·布拉德利（Nathaniel Bradley）的纳斯达克专访，该视频现已发布于 https://vimeo.com/1176174810 关于 Datavault AI Inc.Datavault AI™（纳斯达克代码：DVLT）是 Web 3.0 环境中人工智能驱动的数据体验、资产估值及货币化领域的先驱。公司基于云的平台通过其声学科学和数据科学两大部门提供全面解决方案。Datavault AI的声学科学部门拥有WiSA®、ADIO®和Sumerian®等专利技术，专用于空间及多声道无线高清音频传输。数据科学部门则利用Web 3.0和高性能计算技术，在体育娱乐、生物技术、教育、金融科技、房地产、医疗保健、能源等众多行业中，实现体验式数据感知、估值及安全变现。信息数据交易所®（IDE®）是由纳斯达克金融基础设施公司（Nasdaq Financial Infrastructure）提供技术支持的代币交易所。该公司拥有并运营多家交易所，包括国际元素交易所（IEE）、体育画报交易所（SIx）、纽约互动广告交易所（NYIAX）以及美国政治交易所（APE）。公司总部位于宾夕法尼亚州费城。更多信息请访问 https://www.dvlt.ai。前瞻性陈述：本新闻稿包含《1933年证券法》（经修订）第27A条、《1934年证券交易法》（经修订）第21E条以及《1995年私人证券诉讼改革法案》所界定的“前瞻性陈述”。本新闻稿中除历史事实陈述以外的所有陈述，包括关于公司未来运营、财务状况、前景、计划、目标、预期及意图的陈述，均属前瞻性陈述。诸如“预期”、“相信”、 “可能”、“估计”、“预期”、“打算”、“或许”、“计划”、“潜在”、“预测”、“预测”、“应”、“目标”、“将”、“会”等词语及类似表述旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别性词语。本新闻稿中的前瞻性陈述包括但不限于以下内容：(i) 美国专利申请号 17/842,220、美国专利申请号 17/507,459 以及任何相关外国或延续申请的最终授权、范围、有效性和可执行性； (ii) 本公司已获专利及正在申请专利的技术的商业价值、市场采用情况及收入贡献，包括DataValue®、DataScore®、信息数据交换®（IDE®）、Sumerian®加密锚点以及Datavault®平台； (iii) 本公司实现2026年至少2亿美元营收目标的能力；(iv) 本公司正在推进的代币化合同、许可协议及战略合作伙伴关系； (v) 代币化实物资产、数据变现及数字资产税务申报市场的规模、增长态势及发展时机；(vi) 公司预期部署的边缘GPU集群及高性能计算基础设施的集成与运行表现；以及 (vii) 因美国国税局1099-DA表格申报要求而产生的自动化税务申报解决方案需求。这些前瞻性陈述基于管理层目前的预期和假设，并受重大风险、不确定性及其他因素的影响，这些因素可能导致实际结果与明示或暗示的结果存在重大差异。此类风险包括但不限于：美国专利商标局在复审时将已获授权的权利要求范围缩小，或驳回已获授权的权利要求；本公司专利及专利申请中技术的商业化进程出现延迟或失败；本公司吸引和留住客户、被许可方及交易所合作伙伴的能力；来自现有及新兴技术的竞争； 网络安全、区块链协议及量子计算风险；影响数字资产申报的美国联邦及州税法变更（包括对1099-DA表格制度的修改）；影响数字资产、证券、数据隐私及代币化实物资产的监管动态； 本公司按可接受条款筹集额外资金的能力；宏观经济及资本市场状况；以及本公司截至2025年12月31日财政年度的10-K表年度报告、后续10-Q表季度报告、 8-K表当前报告以及向美国证券交易委员会（“SEC”）提交的其他文件中讨论的其他风险因素，上述文件的副本可免费从SEC网站www.sec.gov获取。除适用法律要求外，本公司不承担任何义务，并明确声明不负有任何责任，无论因新信息、未来事件、情况变化或其他原因，均不更新或修订任何前瞻性陈述。投资者和证券持有人应注意，切勿过度依赖这些前瞻性陈述，因其仅反映本新闻稿发布之日的状况。本公司不保证其预期能够实现。本新闻稿不构成出售任何证券的要约，亦不构成购买任何证券的要约邀请。关于潜在收购、处置、合资企业、战略联盟、许可交易或类似安排的任何前瞻性陈述，均受最终协议的谈判、签署和履行以及惯常交割条件的满足所制约，且无法保证此类交易将按预期条款、预期时间完成，甚至可能无法完成。行业与市场数据：本新闻稿包含基于或源自独立行业出版物、第三方研究、调查及报告的行业、市场及竞争地位数据，包括统计数据、预测及推算，其中涉及RWA.xyz、波士顿咨询集团（Boston Consulting Group）、ADDX、SkyQuest Technology以及美国国税局（U.S. Internal Revenue Service）提供的数据。本公司未独立核实此类第三方信息的准确性或完整性，且对其可靠性不作任何明示或暗示的陈述或保证。此类行业出版物及预测本质上受制于假设、方法论限制及不确定性，基于此类数据的推测、估计及判断可能并不准确。实际市场规模、增长率以及本公司在这些市场中的地位可能与本文所述数据存在重大差异。商标、商号、服务标记及版权：Datavault AI™、DataValue®、DataScore®、Information Data Exchange®、IDE®、Datavault®、WiSA®、ADIO® 及 Sumerian® 是 Datavault AI Inc. 在美国及/或其他司法管辖区的商标、服务标记或注册商标。本新闻稿还涉及其他公司拥有的商标、服务标记、商号及版权，包括 Coinbase、Kraken、Gemini 和 Nasdaq 的相关标识。仅为方便起见，本新闻稿中提及的某些商标、服务标记、商号及版权可能未标注™、®、©或SM符号，但本公司将在适用法律允许的最大范围内，对其自有商标、服务标记、商号及版权主张权利。使用或展示其他方的商标、服务标记、商号或版权，并非旨在且不暗示本公司与任何此类第三方存在关系，亦不构成对该等第三方的认可或赞助。媒体联系：marketing@dvlt.ai 投资者联系：Edward Barger投资者关系副总裁ebarger@dvlt.ai | ir@dvlt.ai 来源：Datavault AI Inc Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent.Key Highlights for InvestorsOne newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated data valuation & monetization, tokenized virtual location funding, and automated tax return preparation for digital assets and DeFi-directly addressing 1099-DA compliance challenges.Reinforces the Company's Sumerian® Crypto Anchors, DataValue®, DataScore®, and Information Data Exchange® (IDE®) technologies with quantum-resistant encryption and blockchain immutability, underpinning a growing pipeline of tokenization contracts and licensing deals.Arrives as the first full IRS Form 1099-DA filing season closes amid reported operational hurdles-including late deliveries by Coinbase, Kraken, and Gemini-demonstrating clear demand for Datavault AI's automated, tokenized tax solutions.Enabled use cases include tokenized commodities (copper, gold, precious metals), agricultural/genomic/healthcare data assets, NIL digital twins, funded virtual biotech marketplaces, and intelligent tax automation-integrating natively with the Company's edge GPU fleet and HPC infrastructure.Directly supports Datavault AI's 2026 revenue target of at least $200 million, accelerates commercialization across fintech, healthcare, biotech, energy, agriculture, sports & entertainment, and Web3, and opens new licensing and partnership opportunities.Scope of the Latest ProtectionsU.S. Patent No. 12,596,819 - "Method and System for Data Valuation and Secure Commercial Monetization Platform" (issued): Covers an end-to-end permissioned platform spanning opt-in data contribution, AI-driven automated valuation, blockchain-tokenized storage in the Datavault®, and trading on open exchanges with flexible compensation pathways (sales, licenses, rewards, charitable contributions).U.S. Patent Application No. 17/842,220 - "System and Method for Funding a Virtual Location" (Notice of Allowance): Protects the funding, authentication, and tokenized operation of organization-specific virtual locations, including multi-currency donations, integrated event and asset tokenization, portfolio-aligned advertising, and compensation mechanisms for data contributors.U.S. Patent Application No. 17/507,459 - "Platform and Method for Preparing a Tax Return" (Notice of Allowance): Covers automated tax return preparation for clients and employees, with specialized tokenized return handling for digital asset and DeFi activity, back-end form processing, and dynamic adjustment to evolving tax codes-precisely targeting the reconciliation burdens and visibility gaps plaguing the inaugural 1099-DA season.Market Context & TailwindsThe filings position Datavault AI at the convergence of three rapidly expanding markets. Tokenized real-world assets have already surpassed $30 billion in on-chain value (RWA.xyz 2025 data), with Boston Consulting Group and ADDX projecting the global market to exceed $16 trillion by 2030. The global data monetization market is forecast to grow from $7.53 billion in 2024 to $18.8 billion by 2033 (10.7% CAGR, SkyQuest Technology). The new tax-preparation patent arrives precisely as U.S. taxpayers navigate the first full season under the IRS Form 1099-DA digital asset broker reporting regime-where gross proceeds reporting began January 1, 2025, and basis reporting for certain transactions took effect January 1, 2026-amid well-documented industry friction around late broker filings and cross-wallet/chain/DeFi reconciliation.Investor Implications & Strategic OutlookCollectively, the issued patents and allowed applications extend IP coverage around innovations that transform raw data into tokenized, tradable assets and enable transparent funding, monetization, and automated tax handling of virtual environments and digital asset portfolios. These technologies are expected to integrate seamlessly with Datavault AI's anticipated edge GPU fleet and high-performance computing infrastructure, accelerating AI valuation processing and tokenization contract execution."Securing this issued patent and receiving Notices of Allowance on two additional applications validates our leadership in turning intangible data into verifiable, monetizable capital, and in enabling organizations to fund and operate virtual worlds with full transparency and user compensation," said Nathaniel T. Bradley, Founder and Chief Executive Officer of Datavault AI. "These filings deepen our competitive moat and accelerate our path to capturing meaningful share in the data asset, real-world asset, and digital asset tax-preparation markets-directly fueling our $200 million 2026 revenue target and expanding pipeline of tokenization contracts."For additional insight into Datavault AI's growth strategy, commercialization roadmap, and long-term vision for unlocking value from data and intellectual property through tokenization and licensing, investors are encouraged to view the recent Nasdaq interview with CEO Nathaniel Bradley, hosted by Tech Edge and now available at https://vimeo.com/1176174810About Datavault AI Inc.Datavault AI™ (NASDAQ:DVLT) is a pioneer in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform delivers comprehensive solutions across its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless, high-definition sound transmission. The Data Science Division harnesses Web 3.0 and high-performance computing to enable experiential data perception, valuation, and secure monetization across industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE®) is a token exchange technology powered by Nasdaq Financial Infrastructure. The Company owns and operates exchanges, including International Elements Exchange (IEE), Sports Illustrated Exchange (SIx), New York Interactive Advertising Exchange (NYIAX), and American Political Exchange (APE). The Company is headquartered in Philadelphia, PA. Learn more at https://www.dvlt.ai.Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding the Company's future operations, financial position, prospects, plans, objectives, expectations, and intentions, are forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the ultimate issuance, scope, validity, and enforceability of U.S. Patent Application No. 17/842,220, U.S. Patent Application No. 17/507,459, and any related foreign or continuation applications; (ii) the commercial value, market adoption, and revenue contribution of the Company's patented and patent-pending technologies, including DataValue®, DataScore®, the Information Data Exchange® (IDE®), Sumerian® Crypto Anchors, and the Datavault® platform; (iii) the Company's ability to achieve its 2026 revenue target of at least $200 million; (iv) the Company's pipeline of tokenization contracts, licensing arrangements, and strategic partnerships; (v) the size, growth, and timing of the markets for tokenized real-world assets, data monetization, and digital-asset tax preparation; (vi) the integration and performance of the Company's anticipated edge GPU fleet and high-performance computing infrastructure; and (vii) the demand for automated tax-preparation solutions arising from IRS Form 1099-DA reporting requirements.These forward-looking statements are based on management's current expectations and assumptions and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks include, among others: the U.S. Patent and Trademark Office issuing claims narrower than those allowed or rejecting allowed claims on reexamination; delays or failures in commercializing the Company's patented and patent-pending technologies; the Company's ability to attract and retain customers, licensees, and exchange partners; competition from existing and emerging technologies; cybersecurity, blockchain protocol, and quantum-computing risks; changes in U.S. federal and state tax law affecting digital-asset reporting, including modifications to the Form 1099-DA regime; regulatory developments affecting digital assets, securities, data privacy, and tokenized real-world assets; the Company's ability to raise additional capital on acceptable terms; macroeconomic and capital-markets conditions; and the other risk factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings made with the U.S. Securities and Exchange Commission (the "SEC"), copies of which are available free of charge on the SEC's website at www.sec.gov.Except as required by applicable law, the Company undertakes no obligation, and expressly disclaims any duty, to update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company gives no assurance that it will achieve its expectations. This release does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any forward-looking statements regarding potential acquisitions, dispositions, joint ventures, strategic alliances, licensing transactions, or similar arrangements are subject to the negotiation, execution, and consummation of definitive agreements and the satisfaction of customary closing conditions, and no assurance can be given that any such transaction will be completed on the terms contemplated, on the timing anticipated, or at all.Industry and Market Data: This press release contains industry, market, and competitive position data, including statistics, forecasts, and projections, that are based on or derived from independent industry publications, third-party research, surveys, and reports, including data attributed to RWA.xyz, Boston Consulting Group, ADDX, SkyQuest Technology, and the U.S. Internal Revenue Service. The Company has not independently verified the accuracy or completeness of any such third-party information and makes no representation or warranty, express or implied, as to its reliability. Industry publications and forecasts of this nature are inherently subject to assumptions, methodological limitations, and uncertainties, and projections, estimates, and beliefs based on such data may not prove to be accurate. Actual market size, growth rates, and the Company's position within these markets may differ materially from the figures presented herein.Trademarks, Trade Names, Service Marks and Copyrights: Datavault AI™, DataValue®, DataScore®, Information Data Exchange®, IDE®, Datavault®, WiSA®, ADIO®, and Sumerian® are trademarks, service marks, or registered trademarks of Datavault AI Inc. in the United States and/or other jurisdictions. This press release also refers to trademarks, service marks, trade names, and copyrights owned by other companies, including those of Coinbase, Kraken, Gemini, and Nasdaq. Solely for convenience, certain of the trademarks, service marks, trade names, and copyrights referred to in this press release may be listed without the ™, ®, ©, or SM symbols, but the Company will assert, to the fullest extent under applicable law, its rights to its own trademarks, service marks, trade names, and copyrights. The use or display of other parties' trademarks, service marks, trade names, or copyrights is not intended to and does not imply a relationship with, or endorsement or sponsorship by, the Company of any such third party.Media Contact:marketing@dvlt.aiInvestor Contact:Edward BargerVP Investor Relationsebarger@dvlt.ai | ir@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

吉隆坡, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 万利集团（以下简称"万利"或"集团"）之上市实体 CBL International Limited（以下简称"公司"或"CBL"）（美国纳斯达克交易所代码：BANL），亚太地区知名燃油供应服务商，今日宣布收购英属维尔京群岛注册公司绿燃控股有限公司（"绿燃"）50.5%的多数股权。CBL的全资子公司作为《股份出售及购买协议》（简称"SPA"）的直接签约方，而CBL并非该协议的签约方，因此CBL向卖方提供公司担保，以确保其子公司履行SPA项下的付款义务。绿燃在马来西亚经营两项互补业务：可持续航空燃料（SAF）和生物燃料的原料贸易，以及船舶生物燃料供应兼传统燃料油加注服务。其原料贸易部门持有所必要的国际认证资质以便采购和交易SAF及生物燃料生产所需原材料，并拥有成熟的供应商与客户网络。燃料油加注业务则持有当地政府发出的许可证，可在马来西亚水域供应传统船用燃料及生物燃料。此次战略投资符合全球日益重视环境、社会和治理（ESG）以及海事、航空领域监管要求不断演变的趋势。CBL的财务资源及船用燃料物流运营专长预计将助力绿燃业务扩张，使其能够扩大原料贸易规模，并探索向马来西亚SAF相关生产企业供应原材料的业务。马来西亚可持续燃料的基础设施投资日益增加，该国已有新的商业规模SAF生产设施投入运营，并有更多项目正在规划中。这些发展进一步凸显了该地区对原料的潜在需求。在燃料油加注业务方面，绿燃的供应资质令集团得以在包括巴生港在内的马来西亚主要港口发展传统燃料和生物燃料的供应能力。巴生港是全球吞吐量前十的港口之一。这将依托CBL现有的燃料油加注服务，支持行业迈向低碳船用燃料转型。CBL集团主席兼行政总裁谢威廉博士评论道："此次收购是在可持续能源供应链上采取稳健拓展的一步，并充分利用了我们在船用燃料服务方面的核心优势。我们期待与绿燃团队合作，支持这些业务按照市场发展实现负责任增长。"此次交易预计将增强CBL在不断演变的海洋与能源领域的长期定位，同时不会改变公司对现有加燃料服务业务的核心专注。关于万利集团万利集团成立于2015年，以 CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。截至2026年4月17日，我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布澳大利亚、比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、荷兰、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖超过70个港口。集团积极推动可持续燃料的使用，并已取得ISCC EU 和 ISCC Plus 认证，以及EcoVadis银牌。如欲瞭解更多信息，請到集團網站 https://www.banle-intl.com 瀏覽。前瞻性声明本公告中的某些陈述并非历史事实，而是前瞻性陈述。前瞻性陈述一般使用"相信"、"可能"、"可以"、"将要"、"估计"、"继续"、"预期"、"打算"、"期望"、"计划"、"应该"、"将会"、"未来"、"展望"、"潜力"、"项目"等类似词语来预测或表达未来事件或趋势或不属于历史事项的陈述，但不使用这些词语并不意味着陈述并非前瞻性。这些前瞻性陈述包括但不限于对其他绩效指标的估计和预测，以及对市场机会的预测。这些信息涉及已知和未知的风险和不确定性，并基于各种假设（无论本新闻稿中是否指明）以及BANL管理层的当前预期，而非对实际业绩的预测。这些前瞻性陈述仅供说明目的，不得被任何投资者作为且不得被依赖为对事实或可能性的担保、保证、预测或确凿陈述。实际事件和情况难以或不可能预测，也会与假设不同。许多实际事件和情况不在BANL的控制范围内。一些重要因素可能导致实际结果与任何前瞻性陈述存在实质性差异，包括国内外商业、燃料价格及关税、市场、金融、政治和法律环境的变化。公司没有义务公开更新或修改任何前瞻性陈述来反映随后发生的事件或情况或预期的变化，除非法律要求。尽管公司认为该等前瞻性陈述中表达的预期合理，但不能向您保证此类预期最终正确无误。公司提醒投资者实际结果可能与预期结果存在重大差异，并鼓励投资者细阅公司的注册声明和向SEC提交的其他文件所载可能影响其未来业绩的其他因素。CBL INTERNATIONAL LIMITED （注册于开曼群岛的有限责任公司）如需更多信息，請聯繫：CBL International Limited電郵：investors@banle-intl.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - April 22, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Stuart Watson — former global Head of Technical Development for Rio Tinto Ltd. (ASX: RIO), one of the largest mining and mineral production companies in the world, has joined GMG as Chief Production Growth Officer.Stuart has over 30 years of global leadership experience in metals and mining and oil and chemicals, including 20 years at Rio Tinto, across operations, sales and marketing, mergers and acquisitions, and technology development and innovation. Career highlights include:Leading and delivering multiple major transformation programs valued over US$5 Billion and merger and acquisition deals valued at US$1 Billion.Directing US$1 Billion in global technology and research & development spend to create breakthrough growth options and projectsBuilding high-performing global teams across Asia, Europe, and North AmericaStuart has a Master of Business Administration (MBA) - Henley Management College, UK; is a Chartered Engineer - Institute of Chemical Engineers (IChemE), has a Masters of Engineering, Chemical Engineering (First Class Honours) — Imperial College, University of London and Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique (ENSIGC), Toulouse, France.Craig Nicol, CEO & Managing Director of the Company, commented "We welcome Stuart to the GMG team - he is a great addition to the Senior Executive Team for both executive leadership and delivery capability. I will enjoy working with Stuart to expand our production across our graphene and graphene products around the world."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "On behalf of the board I welcome Stuart to the team and look forward to the progress around expanding our production capability into North America."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating. GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and in the end, reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia. GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/293781_d1c07d1d84356a2d_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293781 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Transaction will create a global powerhouse for mining finance and reduce complexity and costs for Canadian market participantsAcquisition will strengthen TMX's ability to serve clients across the capital markets ecosystem, expands global presence, accelerates growth strategyAnalyst webcast and conference call on Wednesday, April 22, 2026 at 8:00am EDT to discussToronto, Ontario--(ACN Newswire via SeaPRwire.com - April 22, 2026) - TMX Group Limited (TSX: X) (TMX Group) announced today an agreement to acquire Middlebury Holdings Pty. Limited (Cboe Australia) and Cboe Canada Holdings, ULC (Cboe Canada) from Cboe Global Markets, Inc. for US$300 million ($409 million*) in total consideration, a transaction that will bolster TMX's ability to serve clients across the capital markets ecosystem, expand the company's global presence, and accelerate the company's growth strategy, while reducing cost and complexity for Canadian market participants."We are tremendously excited to announce the acquisition of Cboe Australia and Cboe Canada, a deal that represents a unique opportunity to strengthen our domestic marketplace for clients and the entire stakeholder ecosystem, while expanding the reach and impact of our presence in a region of the world we know well," said John McKenzie, Chief Executive Officer, TMX Group. "We look forward to working with our industry partners to ensure a smooth transition, and to exploring innovative ways to serve the needs of issuers and investors across the Australian market, while continuing to seek out opportunities to accelerate our enterprise growth strategy."Cboe Australia and Cboe Canada offer equities trading venues, listing venues and market data solutions. Cboe Australia is an innovative securities exchange offering companies strategic tailored support for public market listings, including ETFs, as well as structured products and warrants, and providing a trading venue for brokers and investors with efficient and cost-effective access to local and global investment opportunities. Cboe Australia was also recently granted a license for corporate listings. Cboe Canada includes MATCHNow, NEO-L, NEO-N, and NEO-D, as well as ETF, CDR and corporate listings."The teams at Cboe Australia and Cboe Canada have delivered consistent performance and built resilient, high-quality markets," said Craig Donohue, Chief Executive Officer, Cboe Global Markets. "These businesses are well positioned for their next chapter, and we will work closely with TMX, our local regulators, and our clients to ensure a seamless transition."Transaction HighlightsTMX's acquisition of Cboe Australia will bring together the world's leading mining and energy transition financing ecosystems, unlocking potential to innovate for a growing global client base.TMX's acquisition of Cboe Canada enhances the quality of client experience across domestic equities marketplaces:Increasing efficiency of access to capital and liquidity for Canadian issuers, andReducing direct and indirect costs for participants, while improving execution quality and resiliency.Transaction expected to be accretive to adjusted earnings per share within the first 12 months of closing, excluding synergies.Revenue growth expected to be in-line with TMX's long-term financial objectivesCombined Cboe Canada and Cboe Australia businesses delivered revenue of approximately $87 million in 2025, and adjusted EBITDA of approximately $25 million**.Further Transaction DetailsThe purchase of each business is subject to regulatory approvals and customary closing conditions in Australia and Canada. The two components of this acquisition, Cboe Australia and Cboe Canada, are expected to close separately, each after required approvals have been obtained.Canaccord Genuity and Macquarie Capital are acting as financial advisors to TMX Group. FGS Longview is acting as strategic communications advisor to TMX Group.*Based on USD/CAD exchange rate of 1.3644 at April 21, 2026. Actual amounts in Canadian dollars are subject to change.**Based on average AUD/CAD of 0.90 for 2025. Cboe Australia and Canada revenue and EBITDA are compilations of financial information provided to us for the Cboe entities as of December 31, 2025. The Cboe financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies.Teleconference / Audio WebcastTMX Group will host a teleconference / audio webcast to discuss the transaction.Time: 8:00 a.m. - 9:00 a.m. ET on Wednesday, April 22, 2026Participants may access the conference call via the webcast link: https://www.gowebcasting.com/14669.The audio webcast of the conference call and investor presentation will also be available on TMX Group's website at www.tmx.com, under Investor Relations.Alternatively, participants may join the live call by dialing 1-833-752-4317 or 1-647-846-2266.An audio replay of the conference call will be available at 1-855-669-9658 or 1-412-317-0088, [access code 6830744].Caution Regarding Forward-Looking InformationThis press release of TMX Group Limited ("TMX Group", "us", "we", "our") contains "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, assumptions, estimates, projections and other factors that management believes to be relevant as of the date of this press release. Often, but not always, such forward-looking information can be identified by the use of forward-looking words such as "plans", "expects", "projects", "is expected", "projected", "budget", "scheduled", "targeted", "estimates", "forecasts", "intends", "anticipates", "believes", or variations or the negatives of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved or not be taken, occur or be achieved. Forward-looking information, by its nature, requires TMX Group to make assumptions and is subject to significant risks and uncertainties which may give rise to the possibility that our expectations or conclusions will not prove to be accurate and that our assumptions may not be correct. Examples of forward-looking information in this press release include, but are not limited to, the anticipated benefits of the transactions to TMX Group, Cboe Canada and Cboe Australia; the expected impact on TMX Group's earnings and Adjusted earnings per share; expectations regarding the revenue growth of Cboe Canada and Cboe Australia; the ability to integrate Cboe Canada and Cboe Australia into TMX Group and the potential synergies; the expected impact on TMX's long-term growth strategy and transformational objectives; the potential for geographic expansion; the ability for TMX Group to accelerate Cboe Canada and Cboe Australia's growth; the timing and receipt of regulatory approval; and closing of the transaction, each of which is subject to a number of significant risks and uncertainties. These risks include, but are not limited to: competition from other exchanges or marketplaces, including alternative trading systems and new technologies, on a national and international basis; dependence on the economies of Canada, the United States and Australia; adverse effects on our results caused by global economic conditions (including geopolitical events, interest rate movements or threats of recession) or uncertainties including changes in business cycles that impact our sector; failure to retain and attract qualified personnel; geopolitical and other factors which could cause business interruption; dependence on information technology; vulnerability of our networks and third party service providers to security risks, including cyber attacks; failure to properly identify or implement our strategies; regulatory constraints; constraints imposed by our level of indebtedness, risks of litigation or other proceedings; dependence on adequate numbers of customers; failure to develop, market or gain acceptance of new products; failure to close and effectively integrate acquisitions, including the Cboe Canada and Cboe Australia acquisition, to achieve planned economics or divest underperforming businesses; currency risk; adverse effect of new business activities; adverse effects from business divestitures; not being able to meet cash requirements because of our holding company structure and restrictions on paying inter-corporate dividends; dependence on third party suppliers and service providers; dependence of trading operations on a small number of clients; risks associated with our clearing operations; challenges related to international expansion; restrictions on ownership of TMX Group common shares; inability to protect our intellectual property; adverse effect of a systemic market event on certain of our businesses; risks associated with the credit of customers; cost structures being largely fixed; the failure to realize cost reductions in the amount or the time frame anticipated; dependence on market activity that cannot be controlled; the regulatory constraints that apply to the business of TMX Group and its regulated subsidiaries, costs of on exchange clearing and depository services, trading volumes (which could be higher or lower than estimated) and the resulting impact on revenues; future levels of revenues being lower than expected or costs being higher than expected.Forward-looking information is based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions with respect to the impact of the cost of acquisition financing on adjusted earnings per share; assumptions in connection with the ability of TMX Group to successfully compete against global and regional marketplaces and other venues; business and economic conditions generally; exchange rates (including estimates of exchange rates from Canadian dollars to the U.S. dollar, British pound sterling, or Australian dollar), commodities prices, the level of trading and activity on markets, and particularly the level of trading in TMX Group's key products; business development and marketing and sales activity; the continued availability of financing on appropriate terms for future projects; changes to interest rates and the timing thereof; productivity at TMX Group, as well as that of TMX Group's competitors; market competition; research and development activities; the successful introduction and client acceptance of new products and services; successful introduction of various technology assets and capabilities; the impact on TMX Group and its customers of various regulations; TMX Group's ongoing relations with its employees; and the extent of any labour, equipment or other disruptions at any of its operations of any significance other than any planned maintenance or similar shutdowns.In addition to the assumptions outlined above, forward looking information related to long term revenue CAGR objectives, and long term adjusted earnings per share CAGR objectives are based on assumptions that include, but not limited to:TMX Group's success in achieving growth initiatives and business objectives;continued investment in growth businesses and in transformation initiatives including next generation technology and systems;no significant changes to our effective tax rate, and number of shares outstanding;organic and inorganic growth in recurring revenuemoderate levels of market volatility over the long term;level of listings, trading, and clearing consistent with historical activity;economic growth consistent with historical activity;no significant changes in regulations;continued disciplined expense management across our business;continued re-prioritization of investment towards enterprise solutions and new capabilities;free cash flow generation consistent with historical run rate; anda limited impact from inflation, rising interest rates and supply chain constraints on our plans to grow our business over the long term including on the ability of our listed issuers to raise capital.While we anticipate that subsequent events and developments may cause TMX Group's views to change, TMX Group has no intention to update this forward-looking information, except as required by applicable securities law. This forward-looking information should not be relied upon as representing TMX Group's views as of any date subsequent to the date of this press release. TMX Group has attempted to identify important factors that could cause actual actions, events or results to differ materially from those current expectations described in forward-looking information. However, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended and that could cause actual actions, events or results to differ materially from current expectations. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are not intended to represent a complete list of the factors that could affect TMX Group. Important additional information identifying risks and uncertainties and other factors is contained in TMX Group's 2025 Annual Report under the headings entitled "Caution Regarding Forward-Looking Information" and "Enterprise Risk Management" which may be accessed at tmx.com in the Investor Relations section under Regulatory Filings.Non-GAAP Financial MeasuresThis press release includes references to financial measures that are not defined by GAAP. Although such non-GAAP measures are calculated according to accepted industry practice, such measures disclosed in this press release may be different from non-GAAP measures used by other companies. This data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. While TMX Group believes these measures provide investors with greater transparency and supplemental data relating to the transaction, readers are cautioned that these non-GAAP measures are not alternatives to measures determined in accordance with GAAP and should not, on their own, be construed as indicators of TMX Group's or Cboe Canada and Cboe Australia's future performance or profitability. Readers should not rely on any single financial measure when evaluating TMX Group's business or that of Cboe Canada and Cboe Australia. We use non-GAAP measures and non-GAAP ratios that do not have standardized meanings prescribed by GAAP and are, therefore, unlikely to be comparable to similar measures presented by other companies. Management uses these measures, and excludes certain items, because it believes doing so provides investors a more effective analysis of underlying operating and financial performance, including, in some cases, our ability to generate cash and our ability to repay debt. Management also uses these measures to more effectively measure performance over time, and excluding these items increases comparability across periods. The exclusion of certain items does not imply that they are non-recurring or not useful to investors.Adjusted earnings per share provided above is a non-GAAP ratio and does not have a standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. TMX Group presents Adjusted EPS and excludes, among other things, acquisition, integration, and related items; amortization of intangibles related to acquisitions; strategic re-alignment expenses; dispute, litigation and related items; and other items as disclosed in TMX Group's 2025 Annual Report. For more information on Adjusted EPS, including definitions and explanations of how these measures provide useful information, refer to Non-GAAP Measures in TMX Group's 2025 Annual Report.Adjusted EBITDA is calculated as net income excluding interest expense, income tax expense, depreciation and amortization, acquisition, integration, and related costs, one-time income (loss), and other significant items that are not reflective of the underlying business operations of Cboe Canada and Cboe Australia. Cboe Canada and Cboe Australia Adjusted EBITDA is a compilation of financial information provided to us for Cboe Canada and Cboe Australia entities as of December 31, 2025. The Cboe Canada and Cboe Australia financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies. Adjusted EBITDA for Cboe Canada and Cboe Australia excludes certain items such as discontinued operations, transfer pricing, unrealized gains / losses, and one-time employee costs.About TMX Group (TSX: X) TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, TSX Trust, TMX Trayport, TMX Datalinx, TMX VettaFi and TMX Newsfile, which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Singapore, and Vienna. For more information about TMX Group, visit www.tmx.com. Follow TMX Group on X: @TMXGroup.For more information please contact:Catherine KeeHead of Media RelationsTMX Group416-671-1704catherine.kee@tmx.comAmanda TangHead of Investor RelationsTMX Group416-895-5848amanda.tang@tmx.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293729 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key therapeutic areas including oncology, metabolic, cardiovascular, and immunological diseases.Business development has become a recurring and increasingly important growth driver, with RMB 787 million in out-licensing revenue recognized during the quarter, primarily from the collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions, including out-licensing, NewCo structures, and strategic alliance models.A key milestone during the period was the successful Nasdaq listing of Kailera Therapeutics (NASDAQ: KLRA), a NewCo company built around Hengrui Pharma’s GLP-1-based assets. This milestone reflects continued progress in executing the Company’s NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.Looking ahead, Hengrui Pharma will remain committed to innovation and globalization, strengthening its pipeline and advancing the development and commercialization of innovative therapies to benefit patients worldwide. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 4月20日，云顶新耀宣布在2026年美国癌症研究协会（AACR）年会上公布其自主研发的mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂（替雷利珠单抗）治疗晚期实体瘤的首次人体临床试验（FIH）数据。结果显示出良好的安全性和耐受性、显著的免疫原性及积极的初步疗效信号，支持进一步临床开发的推进。据悉，该临床试验由北京大学肿瘤医院与复旦大学附属肿瘤医院联合发起（EVM16CX01，NCT06541639），并于2025年3月完成首例患者给药。EVM16CX01是一项评估EVM16注射液单药及联合PD-1抑制剂治疗对晚期或复发实体瘤患者的安全性、耐受性、免疫原性和初步疗效的剂量递增及扩展研究，该试验采用3+3 剂量递增设计，包括三个剂量组：0.1 mg、0.3 mg和1.0 mg。入选患者为经标准治疗失败的晚期或复发性实体瘤患者，且至少有一个可测量靶病灶。患者将接受2次EVM16单药治疗（每两周一次），随后接受EVM16联合替雷利珠单抗治疗。截至2025年12月7日，共入组9例患者。安全性和耐受性方面，EVM16未观察到剂量限制性毒性（DLT）。所有患者均报告至少一次与研究药物相关的不良事件，均为2级及以下，且均可自行缓解。 EVM16在9例患者中有8例诱导出强烈的新抗原特异性T细胞免疫反应，并显示出剂量依赖性趋势。初步临床疗效方面，一例既往接受过三线系统治疗失败的胃食管结合部癌患者达到确认的部分缓解（PR），无进展生存期（PFS）为126天。另有2例患者达到疾病稳定(SD)，其中一例既往接受过三线系统治疗失败的非小细胞肺癌患者PFS为88天，另一例既往接受过三线系统治疗失败的食管鳞癌患者截至数据截止日已随访112天，尚未观察到疾病进展。北京大学肿瘤医院消化肿瘤内科主任、中国临床肿瘤学会胃癌专家委员会主任委员沈琳教授表示："EVM16作为一款新型mRNA个性化肿瘤治疗性疫苗，在首次人体临床试验中展现出良好的临床开发潜力。数据显示，该疫苗在晚期实体瘤患者中整体安全性与耐受性良好，未观察到剂量限制性毒性。在免疫学层面，EVM16能够诱导新抗原特异性T细胞应答，并呈现一定剂量依赖趋势，提示其具有较强的免疫激活能力。在疗效探索方面，临床试验在既往接受多线标准治疗失败的患者中观察到初步抗肿瘤活性信号，包括部分缓解（PR）及疾病稳定（SD），显示其免疫学作用机制具有改善临床获益的潜力。总体而言，该临床试验初步验证了EVM16通过新抗原驱动T细胞应答实现肿瘤免疫激活的临床价值，为其后续临床开发提供了重要依据。当前，尽管免疫检查点抑制剂已显著改善部分肿瘤的治疗格局，但总体获益人群仍有限，尤其是在多线治疗失败的晚期实体瘤患者中仍存在显著未满足需求。EVM16所代表的mRNA个性化肿瘤治疗性疫苗治疗路径，有望在现有免疫治疗基础上进一步拓展受益人群，并带来更多治疗选择。"云顶新耀首席执行官罗永庆表示："非常高兴看到EVM16的首次人体临床试验数据在AACR大会上公布。此次公布的在晚期实体瘤患者中展现出良好的安全性与耐受性、疗效及作用机制等方面的积极结果，初步验证了EVM16的治疗潜力和云顶新耀自研mRNA平台的临床价值。对于晚期实体瘤患者而言，尤其是多线治疗失败人群，仍然缺乏有效且具有针对性的治疗选择。EVM16作为公司自主研发的mRNA个性化肿瘤治疗性疫苗，具备诱导免疫激活并产生新抗原特异性T细胞应答的潜力，有望预防肿瘤转移或复发，代表了肿瘤免疫治疗的重要探索方向。该项目基于公司自主研发的EVER-NEO-1‘妙算’肿瘤新抗原人工智能算法系统。该系统可基于患者肿瘤特异性突变进行分析，识别具有较高免疫原性的肿瘤新抗原，并生成相应的mRNA疫苗设计方案，且具备自我迭代优化能力，以持续提升新抗原预测与筛选效率。依托国际领先的mRNA平台，我们将加速推进EVM16后续临床开发工作，推动该创新疗法惠及更多患者。"云顶新耀已成功将经过临床验证的自研AI+mRNA平台本地化，构建了一个涵盖从抗原设计、mRNA序列优化、脂质纳米颗粒（LNP）靶向递送技术到产业化生产的端到端全产业链平台，具备了在全球范围内解决巨大未满足医疗需求的潜力。EVM16是公司自主研发的mRNA个性化肿瘤治疗性疫苗，根据每位患者特有的肿瘤细胞突变，通过EVER-NEO-1"妙算"系统识别具有较高免疫原性的肿瘤新抗原，并设计编码数十种肿瘤新抗原的mRNA治疗性疫苗。EVM16通过LNP靶向递送系统在体内进行高效的抗原呈递，激活患者自身的新抗原特异性T细胞免疫，进而达到杀伤肿瘤细胞和治疗癌症的目的。从投资与市场维度来看，个体化肿瘤疫苗尚处早期突破期。根据Grand View Research的预测，全球个性化癌症疫苗市场规模2030年将达14.5亿美元，2025-2030年复合增长率，高达44.86%。麦高证券指出，mRNA肿瘤疫苗有望实现泛癌种覆盖，同时兼具高可及性、现货化与个性化优势。作为极具潜力的新型肿瘤免疫疗法，其可通过广泛联用，以辅助疗法切入临床，逐步打开数百亿美元的市场空间。在此背景下，云顶新耀在该领域的布局正加速落地，逐步构建具备全球竞争力的研发管线。依托自主AI+mRNA平台与国内率先布局的临床身位，云顶新耀正处于产业化与估值成长的关键节点。本次EVM16首次人体临床试验（FIH）数据的读出，有望进一步释放临床与商业化潜力，进一步吸引市场及投资者持续聚焦，助力公司在肿瘤免疫赛道实现长足的价值跨越。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Apr 20, Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The data include results from EVM16 as a monotherapy and in combination with the PD-1 inhibitor tislelizumab in patients with advanced solid tumors. The results demonstrated that EVM16 has a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy in patients with advanced solid tumors, supporting its further clinical development.The clinical trial (EVM16CX01, NCT06541639) was conducted jointly by Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, with the first patient dosed in March 2025. EVM16CX01 is a first-in-human (FIH), dose-escalation, and expansion study evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with tislelizumab in patients with advanced solid tumors. The study follows a 3+3 dose-escalation design across three dose levels (0.1 mg, 0.3 mg, and 1.0 mg). Eligible patients are those with advanced or recurrent solid tumors who have failed standard of care and have at least one measurable target lesion. Patients receive 2 doses of EVM16 monotherapy once every two weeks, followed by combination therapy of EVM16 and tislelizumab. As of December 7, 2025, a total of 9 patients had been enrolled.No dose-limiting toxicities (DLTs) were observed. All patients experienced at least one investigational product (IP) related adverse event (AE), all of which were Grade ≤ 2 and resolved spontaneously. EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 patients, which showed a dose-dependent trend. A gastroesophageal junction cancer patient who failed 3 prior lines of systemic therapy achieved a confirmed partial response and a PFS of 126 days. Another 2 patients achieved stable disease. A non-small cell lung cancer patient who failed 3 prior lines of systemic therapy achieved a PFS of 88 days, and an esophageal squamous cell carcinoma patient who failed 3 prior lines of systemic therapy has been followed up for 112 days to date and has not experienced disease progression.“As a novel personalized mRNA cancer vaccine, EVM16 has demonstrated encouraging clinical development potential in its first-in-human clinical trial,” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. “The data show a favorable safety and tolerability profile in patients with advanced solid tumors, with no dose-limiting toxicities (DLTs) observed. Importantly, EVM16 stimulated neoantigen-specific T cell responses with a dose-dependent trend, highlighting its consistent immune activation capability. Preliminary anti-tumor activity signals, including partial response (PR) and stable disease (SD), were observed in patients who had failed multiple lines of standard-of-care therapies, suggesting potential clinical activity. These findings provide early clinical validation of EVM16 and reinforce its differentiated mechanism as a personalized mRNA cancer vaccine. While immunotherapies, including checkpoint inhibitors, have transformed the treatment landscape in selected tumor types, most patients, particularly those with heavily pretreated advanced solid tumors, still represent a significant unmet medical need. Personalized mRNA cancer vaccines represented by EVM16 may help expand the population benefiting from immunotherapy and provide additional treatment options.” “The favorable safety, tolerability, immunogenicity, and preliminary efficacy results for EVM16 provide initial evidence of its therapeutic potential and support the clinical value of our in-house mRNA platform,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Patients with advanced solid tumors, particularly those who have failed multiple lines of therapy, continue to suffer from limited treatment options. As our first in-house developed personalized mRNA cancer vaccine, EVM16 demonstrates the ability to induce immune activation and generate neoantigen-specific T cell responses, which may help reduce the risk of tumor metastasis or recurrence. This further underscores its potential as a novel approach in cancer immunotherapy. This project is powered by EVER-NEO-1, Everest’s proprietary AI-based neoantigen prediction algorithm. It analyzes patient-specific tumor mutations to identify highly immunogenic neoantigens and support the design of personalized mRNA vaccine candidates. The algorithm incorporates iterative learning capabilities designed to continuously improve neoantigen prediction accuracy and selection efficiency. Leveraging our leading mRNA platform, we will continue to advance the clinical development of EVM16 and bring this innovative therapy to more patients.”Everest Medicines has localized its clinically validated proprietary AI+mRNA platform, establishing an end-to-end integrated platform spanning antigen design, mRNA sequence optimization, lipid nanoparticles (LNP) targeted delivery and scalable manufacturing, with the potential to address significant unmet medical needs globally.EVM16 is a novel personalized therapeutic mRNA cancer vaccine in-house developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.From an investment and market perspective, personalized cancer vaccines are in an early stage of breakthrough. According to Grand View Research, the global personalized cancer vaccine market is projected to reach $1.45 billion by 2030, with a staggering compound annual growth rate (CAGR) of 44.86% from 2025 to 2030. Myguide Securities points out that mRNA cancer vaccines have the potential to achieve pan-cancer coverage while offering the advantages of high accessibility, “off-the-shelf” availability, and personalization. As a highly promising new form of immunotherapy, it can enter clinical use as adjuvant therapies through extensive combinations, gradually unlocking a market space worth tens of billions of dollars.Against this backdrop, Everest Medicines is accelerating its strategic positioning in this field, progressively building a research and development pipeline with global competitiveness. Leveraging its proprietary AI+mRNA platform and its leading clinical position in China, Everest Medicines is currently at a critical juncture for industrialization and valuation growth. The upcoming readout of first-in-human (FIH) clinical trial data for EVM16 is expected to further release clinical and commercial potential, continuing to attract focus from the market and investors, and helping the company achieve a significant leap in value within the immunotherapy sector. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - 在创新药研发竞争日趋激烈的当下，具备自主研发能力与全产业链布局的中国生物制药企业正加速走向国际资本市场。迈威（上海）生物科技股份有限公司（以下简称"迈威生物"）于4月20日开启公开招股，拟在香港主板上市，进一步拓展全球研发与商业化网络。2025年，迈威生物在业务拓展领域接连取得里程碑式突破，先后完成多项覆盖小核酸、IL-11靶向疗法及长效G-CSF等前沿技术领域的授权合作，累计潜在总金额超过16亿美元。这一系列合作不仅验证了公司平台的研发实力，也为其后续全球临床开发与商业化提供了充沛的资金支持。正是凭借这些重磅合作的持续落地，迈威生物的全球商业化能力逐步凸显，其技术价值正加速转化为可量化的商业回报。对外授权成果显着，验证全球研发价值迈威生物的研发实力已获得国际制药巨头的真金白银认可，其卓越的商业拓展能力成为驱动公司价值增长的核心引擎。2025年，公司总收入达到6.59亿元人民币，同比增长超过2.3倍。其中，对外授权收入达4.09亿元，同比激增超过6倍，这主要得益于与多家国际知名生物科技公司的重磅合作。2025年6月，公司就9MW3811（一款靶向IL-11的人源化单抗）与谷歌系公司Calico达成独家许可协议，授权其在除大中华区外的全球范围内开发和商业化。Calico长期专注于"抗衰老"及年龄相关疾病的生物学研究，在该领域拥有深厚的技术积累，此次合作将加速9MW3811的全球临床开发，进一步提升其在纤维化疾病及癌症治疗领域的国际影响力。9MW3811靶向的IL-11是一种关键的促纤维化细胞因子，在肺纤维化、皮肤瘢痕、肾纤维化、肝纤维化等多种病理进程中扮演核心角色。目前，9MW3811不仅已获批开展特发性肺纤维化临床试验，更于2025年底成为全球首款进入病理性瘢痕（包括增生性瘢痕和瘢痕疙瘩）治疗临床阶段的IL-11靶向药物，为其未来拓展更多纤维化适应症打开了空间。同年10月，迈威生物进一步拓展技术边界，与专注于NewCo孵化的专业机构Aditum Bio就新型双靶点siRNA候选药物达成独家许可协议。Aditum Bio由前诺华高管创立，以其"精准筛选具有巨大潜力的资产，快速推进至临床概念验证，将项目打造成大型制药企业青睐的收购目标"的成熟模式而闻名。此次合作不仅为迈威生物在小核酸药物领域的前瞻性布局引入了国际顶级专业资本的背书，更重要的是，Aditum Bio高效的临床推进能力将大幅缩短该管线的验证周期，有望加速其临床转化进程。深耕相关领域的合作方往往推进意向明确。迈威生物与Disc Medicine就9MW3011（一款靶向TMPRSS6的单克隆抗体）达成的合作正是这一逻辑的体现。双方于2023年1月签署独家许可协议，合同总价值高达4.1亿美元。9MW3011通过调节铁调素水平控制铁过载，为真性红细胞增多症这一尚无有效改良疗法的罕见血液病提供了全新治疗思路。Disc已于2025年9月启动该产品治疗真性红细胞增多症的II期临床试验，至此公司累计收到首付款及I、II期里程碑付款合计2,500万美元。合作的高效推进不仅验证了靶点价值，也为后续更高金额的开发及商业化里程碑奠定了基础。与聚焦早期研发管线的授权合作不同，迈威生物与齐鲁制药围绕已上市产品迈粒生®（长效G-CSF）达成大中华区独家授权合作，借助成熟药企的商业化能力，实现优势互补与风险共担。齐鲁制药在中国肿瘤领域拥有强大的商业化网络和市场渗透能力，双方联手既能加速迈粒生®的市场放量，又能丰富齐鲁制药的产品组合，最大化共享市场红利。技术筑底：源头创新驱动，ADC与TCE双引擎发力密集的BD成果背后，是迈威生物强大的源头创新能力。公司已建立起以自主知识产权的定点偶联技术IDDC™为核心的ADC药物开发平台，以及一体化高效抗体发现平台和T细胞衔接器（TCE）双/三特异性抗体开发平台。其中，IDDC™平台依托四大核心技术DARfinity®（定点偶联）、IDconnect™（稳定连接子分子）、Mtoxin™（新型毒性分子）和LysOnly™（条件释放结构），能够开发出更均匀、更稳定、纯度更高、潜在疗效更好、更安全的优化ADC药物。以核心产品9MW2821（靶向Nectin-4 ADC）为例，该平台通过定点偶联工艺，使产品DAR值均一性超过95%，显著优于传统随机偶联技术，更均一的分子结构带来了更好的稳定性和安全性。值得关注的是，根据美国FDA官网及权威公开资料，已上市的同靶点药物Padcev带有黑框警告，主要涉及严重皮肤反应；而根据迈威生物招股书披露的临床数据，9MW2821在临床试验中展现出良好的安全性，未观察到同类的严重不良事件。疗效方面，9MW2821在尿路上皮癌、三阴性乳腺癌等适应症上均表现出优于Padcev的客观缓解率（ORR）趋势，展现其"同类最佳"潜力。2024年以来，该产品已获得国家药监局突破性疗法认定及FDA多项快速通道与孤儿药资格，国际监管认可度持续提升。迈威生物ADC平台的另一个代表性产品是7MW4911（靶向CDH17 ADC）。 该产品针对的适应症是国内高发的胃肠道肿瘤，患者基数庞大，现有治疗手段仍存在耐药等局限。为应对这一挑战，7MW4911不仅结合创新单抗Mab0727、新型连接子，还采用了专有的Mtoxin™载荷，这是一种专为克服ABC转运蛋白介导的多药耐药机制而设计的强效DNA拓扑异构酶I抑制剂，能有效杀伤耐药肿瘤细胞。目前，7MW4911单药疗法已于2025年11月在中国启动I期临床试验，并于2026年1月在美国启动I/II期临床试验。在TCE领域，迈威生物也取得了实质性进展。公司的6MW5311（靶向CD3/LILRB4）已于近日向国家药监局提交IND申请并获受理，同时其美国临床试验申请目前处于pre-IND阶段，计划于2026年第二季度向FDA正式递交申请。该管线用于治疗复发/难治性急性髓系白血病、慢性粒单核细胞白血病以及复发或难治性多发性骨髓瘤，其独特优势在于：在无肿瘤环境下对T细胞的结合活性极低，而在肿瘤与T细胞共存的微环境中则对肿瘤细胞表现出强效杀伤作用，从而在保障疗效的同时显著提高了安全性。TCE与ADC在肿瘤治疗中机制互补，前者激活T细胞免疫，后者精准杀伤肿瘤细胞。展望未来，迈威生物有望探索二者的联用方案，在肿瘤领域构建起更为广阔和立体的治疗矩阵，释放巨大的管线协同效应。结语全球肿瘤药物市场预计2032年将突破5,400亿美元，ADC、TCE等新一代抗体类药物正重塑精准治疗格局，罕见病与纤维化等领域仍存在巨大未满足需求。凭借扎实的技术平台、前瞻性的管线布局以及卓越的全球商业拓展能力，随着"A+H"两地上市落地，迈威生物将拥有更灵活的资本工具，加速核心产品的全球多中心临床试验、扩充生产产能、深化国际合作。展望未来，公司不仅有望在尿路上皮癌、宫颈癌、三阴性乳腺癌等领域实现关键上市，更将在纤维化疾病、罕见血液病、核酸药物等新赛道持续布局，成长为辐射全球的创新型生物制药领军企业。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

桑尼维尔, 2026年4月22日 - (亚太商讯 via SeaPRwire.com) - GPU加速NVMe存储领域的先驱Graid Technology今日宣布推出其Agentic AI存储产品组合：这是一系列专为消除阻碍“始终在线”生产型AI运行的存储瓶颈而设计的键值缓存解决方案。该产品组合涵盖三个部署层级：KV Cache Server、KV Cache Rack 和 KV Cache Platform，均基于 SupremeRAID™ 技术构建。作为产品组合中最高层级的 KV Cache Platform，其设计与 NVIDIA 的 STX 参考架构高度契合，并计划于 2026 年下半年支持原生 BlueField-4 DPU 执行。随着自主人工智能从实验阶段迈向生产环境，支撑单次推理的基础设施假设已不再成立。运行连续多步骤任务并在数小时运行过程中保持上下文的模型，会产生远超GPU HBM处理能力的KV缓存需求。其结果是：延迟激增至原来的18倍，GPU利用率低至50%，并引发难以检测且恢复成本高昂的模型级故障，包括幻觉和推理能力下降等问题。SupremeRAID™ 直接解决了这一问题，它可将多达 32 块 NVMe 硬盘聚合为一个 280 GB/s 的虚拟存储池，通过 GPU Direct Storage 绕过 CPU，实现 1.3 毫秒的 KV 缓存读取速度——比标准 NVMe 快 77 倍。其三个产品层级可将这一能力应用于各种部署规模：KV Cache Server——为单个推理服务器和边缘 AI 部署提供单节点 NVMe 加速。现已上市。KV Cache Rack——与领先的服务器 OEM 合作伙伴共同设计、经过合作伙伴验证的机架级解决方案，专为企业级多 GPU 集群打造。现已上市。KV Cache Platform——专为英伟达的STX参考架构打造，支持原生BlueField-4 DPU执行，并计划在未来实现机架级存储扩展。“一年前，在 GTC 2025 大会上，黄仁勋曾预言存储将首次实现 GPU 加速。今年，NVIDIA 通过 STX 和 CMX 将这一概念转化为架构，”Graid Technology 首席执行官 Leander Yu 表示。“我们的 KV Cache 产品组合正是为这一时刻而打造，能够以存储层的成本效益，提供自主人工智能所需的存储性能。”对于正在评估代理式人工智能部署的企业和基础设施团队，完整的部署架构、技术规格以及 NVIDIA STX 兼容性详情，请参阅解决方案简介：《Graid Technology 代理式人工智能存储产品组合：专为大规模推理设计的键值缓存解决方案》。如需进一步了解Graid Technology的AI解决方案，请访问 graidtech.com/ai。媒体咨询：Andrea Eaken，美洲及欧洲、中东和非洲地区市场营销高级总监 andrea.eaken@graidtech.com关于 Graid TechnologyGraid Technology 正致力于构建支撑未来人工智能、企业级应用及高性能计算的存储骨干网络。作为全球首款且唯一基于 GPU 的 RAID 技术 SupremeRAID™ 的缔造者，以及英特尔® 虚拟 RAID on CPU（Intel® VROC）的全球技术维护方，Graid Technology 提供灵活的 RAID 解决方案，在最大限度提升 NVMe 性能的同时，为现代数据基础设施提供弹性且可扩展的数据保护。Graid Technology 总部位于硅谷，业务遍及全球，研发中心设在台湾，致力于推动 RAID 技术创新，以满足新一代数据密集型工作负载的需求。如需了解更多信息，请访问 graidtech.com 。来源：Graid Technology Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SUNNYVALE, CA, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026.As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM. The result: latency spikes up to 18x, GPU utilization as low as 50%, and model-level failures, including hallucinations and reasoning degradation, that are difficult to detect and costly to recover from.SupremeRAID™ addresses this directly, aggregating up to 32 NVMe drives into a single 280 GB/s virtual pool, bypassing the CPU via GPU Direct Storage, and delivering KV cache reads at 1.3ms- 77x faster than standard NVMe. The three portfolio tiers bring this capability to every deployment scale:KV Cache Server - single-node NVMe acceleration for individual inference servers and edge AI deployments. Available now.KV Cache Rack - rack-scale, partner-validated solutions co-engineered with leading server OEM partners for enterprise multi-GPU clusters. Available now.KV Cache Platform - Purpose-built for NVIDIA's STX reference architecture, with native BlueField-4 DPU execution and rack-scale storage expansion on the roadmap."A year ago, at GTC 2025, Jensen Huang predicted that storage would become GPU-accelerated for the first time. This year, NVIDIA turned that concept into an architecture with STX and CMX," said Leander Yu, CEO of Graid Technology. "Our KV Cache Portfolio is built for precisely this moment, delivering the storage performance that agentic AI demands, at storage-tier economics."For enterprises and infrastructure teams evaluating agentic AI deployments, the full deployment architecture, technical specifications, and NVIDIA STX compatibility details are available in the solution brief: Graid Technology Agentic AI Storage Portfolio: Purpose-built KV Cache Solutions for Inference at Scale.To learn more about Graid Technology's AI offerings, visit graidtech.com/ai.Media Inquiries:Andrea Eaken, Sr. Director of Marketing, Americas & EMEAandrea.eaken@graidtech.comAbout Graid TechnologyGraid Technology is building the storage backbone for the future of AI, enterprise, and high-performance computing. As the creator of SupremeRAID™, the world's first and only GPU-based RAID, and the global steward of Intel® Virtual RAID on CPU (Intel® VROC), Graid Technology delivers flexible RAID solutions that maximize NVMe performance while ensuring resilient, scalable data protection for modern data infrastructure. Headquartered in Silicon Valley with global operations and R&D in Taiwan, Graid Technology is advancing RAID innovation for the next generation of data-intensive workloads. To learn more, visit graidtech.com.SOURCE: Graid Technology Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com